Johnson & Johnson failed to capitalize on the pulsed field ablation wave in the first quarter of 2025, despite recently launching its Varipulse device in the U.S. The healthcare giant on Tuesday ...

During its quarterly earnings report, executives at Johnson & Johnson said they expect ... after the company’s paused U.S. rollout of its Varipulse pulsed field ablation system, J&J has now ...

The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or ...

Johnson & Johnson and its affiliates 2025 ... the end of the procedure and had a 90% performance goal. iv VARIPURE (VARIPULSE™ Catheter data exchange Platform powered by SECURE) is a SECURE ...

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) will be reporting results tomorrow before market open. Here’s what investors should know. Johnson & Johnson met analysts’ revenue ...

Johnson & Johnson (NYSE ... In electrophysiology, we resumed U.S. VariPulse cases and to date, we have completed more than 5,500 cases globally. Turning to surgery, we recently announced we ...

Additional information on Johnson & Johnson's data presented at HRS can be found here. The VARIPULSE™ Platform consists of the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 ...

"The VARIPULSE™ Platform has both a strong safety ... 3 These multiplatform findings advance the clinical and technical validation of Johnson & Johnson MedTech's PFA portfolio across focal ...